Id: acc0585
Group: 1sens
Protein: PHB
Gene Symbol: PHB1
Protein Id: P35232
Protein Name: PHB1_HUMAN
PTM: phosphorylation
Site: Tyr259
Site Sequence: QLSRSRNITYLPAGQSVLLQL
Disease Category: Cancer
Disease: Ovarian Cancer
Disease Subtype:
Disease Cellline: SK-OV-3
Disease Info:
Drug: platinum
Drug Info: "Cisplatin: A platinum-containing chemotherapeutic agent used in the treatment of various cancers, including testicular, ovarian, and lung cancers, by forming DNA adducts that inhibit cancer cell replication. Carboplatin: A second-generation platinum-based antineoplastic drug with reduced nephrotoxicity compared to cisplatin, commonly employed in ovarian cancer and other malignancies. Oxaliplatin: A third-generation platinum compound effective against colorectal cancer, characterized by its distinct mechanism of action and reduced cross-resistance with other platinum drugs. "
Effect: inhibit
Effect Info: "c-Kit interacts with PHB, promoting the phosphorylation of PHBY259 in membrane rafts, thereby enhancing the motility of ovarian cancer cells and conferring resistance to platinum drugs."
Note:
Score: 5.0
Pubmed(PMID): 32169072
Sentence Index:
Sentence:

Sequence & Structure:

MAAKVFESIGKFGLALAVAGGVVNSALYNVDAGHRAVIFDRFRGVQDIVVGEGTHFLIPWVQKPIIFDCRSRPRNVPVITGSKDLQNVNITLRILFRPVASQLPRIFTSIGEDYDERVLPSITTEILKSVVARFDAGELITQRELVSRQVSDDLTERAATFGLILDDVSLTHLTFGKEFTEAVEAKQVAQQEAERARFVVEKAEQQKKAAIISAEGDSKAAELIANSLATAGDGLIELRKLEAAEDIAYQLSRSRNITYLPAGQSVLLQLPQ

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
EPHB1-Ser899
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.707
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
Y 259 P Ovarian cancer Phosphorylation 32169072
Y 259 U Cervical adenocarcinoma Phosphorylation 22410782

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: